Geynisman, D. M., Burotto, M., Suárez Rodríguez, C., Bourlon, M. T., Huo, S., & Porta, C. (2022). Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.

Geynisman, Daniel M., Mauricio Burotto, Cristina Suárez Rodríguez, Maria T. Bourlon, Stephen Huo, and Camillo Porta. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. 2022.

Geynisman, Daniel M., et al. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. 2022.